{"abstract":"The National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University of Louisville Research Foundation, (\"ULRF\") in its rights to the inventions and patents listed in the Supplementary Information section of this notice. ULRF is a Kentucky 501(c)3 non-profit corporation that is the agent of the University of Louisville (\"UofL\") for licensing intellectual property owned and controlled by ULRF on behalf of UofL.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/12/28/2021-28196.html","cfr_references":[],"citation":"86 FR 73792","comment_url":null,"comments_close_on":"2022-01-12","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center January 12, 2022 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-28196","effective_on":null,"end_page":73793,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/12/28/2021-28196.xml","html_url":"https://www.federalregister.gov/documents/2021/12/28/2021-28196/prospective-grant-of-exclusive-patent-license-griffithsin-compositions-for-treatment-and-prevention","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-28196?publication_date=2021-12-28","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-12-28/2021-28196/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":292,"last_updated":"2026-07-26 18:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-12-28/pdf/2021-28196.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-28196.pdf?1640612744","publication_date":"2021-12-28","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/12/28/2021-28196.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:33:45Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":73792,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: “Griffithsin Compositions for Treatment and Prevention of Anti-Viral Infections”","toc_doc":"Griffithsin Compositions for Treatment and Prevention of Anti-Viral Infections","toc_subject":"Prospective Grant of Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}